for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Navidea Biopharmaceuticals Inc

NAVB.A

Latest Trade

1.23USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.23

 - 

3.12

As of on the Nyse American LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
1.23
Open
--
Volume
--
3M AVG Volume
1.23
Today's High
--
Today's Low
--
52 Week High
3.12
52 Week Low
1.23
Shares Out (MIL)
30.19
Market Cap (MIL)
38.04
Forward P/E
-5.48
Dividend (Yield %)
--

Next Event

Q4 2021 Navidea Biopharmaceuticals Inc Earnings Release

Latest Developments

More

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

Navidea Biopharmaceuticals Says Jed A. Latkin Steps Down As CEO, CFO And COO

Navidea Biopharmaceuticals Q2 Revenue $261,000

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals, Inc. (Navidea) is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company focuses on two drug product diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694, and therapeutic development programs, including therapeutic applications of Manocept platform. It also focuses on developing multiple precision-targeted products based on Manocept platform by identifying the sites and pathways of undetected disease and provide diagnostic services. Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the product developed and commercialized by Navidea based on the platform.

Industry

Biotechnology & Drugs

Contact Info

4995 Bradenton Ave Ste 240

DUBLIN, OH

43017-3552

United States

+1.614.7937500

https://www.navidea.com/

Executive Leadership

Alexander L. Cappello

Chairman of the Board

John K. Scott

Vice Chairman of the Board

Michel Mikhail

Chief Regulatory Officer

Michael Stanley Rosol

Chief Medical Officer

Thomas Forest Farb-Horch

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

-0.760

2020

-0.480

2021(E)

-0.230
Price To Earnings (TTM)
--
Price To Sales (TTM)
54.31
Price To Book (MRQ)
11.17
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-405.14
Return on Equity (TTM)
-145.79

Latest News

Latest News

BRIEF-Navidea Biopharma Announces Full Enrollment In Ongoing Phase 2B Trial Of Tc99m Tilmanocept

* NAVIDEA BIOPHARMACEUTICALS ANNOUNCES FULL ENROLLMENT IN ITS ONGOING PHASE 2B TRIAL OF TC99M TILMANOCEPT IN RHEUMATOID ARTHRITIS (RA)

BRIEF-Navidea Announces Full Enrollment In Ongoing Phase 2B Trial Of Tc99m Tilmanocept

* NAVIDEA BIOPHARMACEUTICALS ANNOUNCES FULL ENROLLMENT IN ITS ONGOING PHASE 2B TRIAL OF TC99M TILMANOCEPT IN RHEUMATOID ARTHRITIS (RA)

BRIEF-Navidea Biopharmaceuticals Files Prospectus Relates To Offering, Resale By Keystone Capital Partners Llc Of Up To 4.6 Mln Shares Of Co's Common Stock

* NAVIDEA BIOPHARMACEUTICALS FILES PROSPECTUS RELATES TO OFFERING, RESALE BY KEYSTONE CAPITAL PARTNERS LLC OF UP TO 4.6 MILLION SHARES OF CO'S COMMON STOCK

BRIEF-Navidea Biopharmaceuticals Announces Acceptance Of Abstract For Presentation At European League Against Rheumatism Congress

* NAVIDEA BIOPHARMACEUTICALS - ANNOUNCES ACCEPTANCE OF ABSTRACT FOR PRESENTATION AT EUROPEAN LEAGUE AGAINST RHEUMATISM CONGRESS Source text for Eikon: Further company coverage:

BRIEF-Navidea Announces Positive Results Of Second Interim Analysis Of Ongoing Phase 2B Study In Rheumatoid Arthritis

* NAVIDEA BIOPHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF SECOND INTERIM ANALYSIS OF ONGOING PHASE 2B STUDY IN RHEUMATOID ARTHRITIS

BRIEF-Navidea Reports Q1 Loss Per Share Of $0.13

* NAVIDEA BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Navidea Biopharmaceuticals Regains Commercialization And Distributions Rights In Europe For Lymphoseek

* NAVIDEA BIOPHARMACEUTICALS REGAINS COMMERCIALIZATION AND DISTRIBUTIONS RIGHTS IN EUROPE FOR LYMPHOSEEK® Source text for Eikon: Further company coverage:

BRIEF-Navidea Biopharmaceuticals Provides Statement On COVID-19 Pandemic

* NAVIDEA BIOPHARMACEUTICALS PROVIDES STATEMENT REGARDING COVID-19 PANDEMIC

BRIEF-Navidea Signs Letter Of Intent With Worldcare Clinical To Partner On Navidea's Rheumatoid Arthritis Clinical Imaging Workflow

* NAVIDEA BIOPHARMACEUTICALS SIGNS LETTER OF INTENT WITH WORLDCARE CLINICAL TO PARTNER ON NAVIDEA’S RHEUMATOID ARTHRITIS CLINICAL IMAGING WORKFLOW AND COMMERCIALIZATION; OTHER BUSINESS UPDATES

BRIEF-Navidea Biopharmaceuticals Announces Issuance Of Patent Extension For Lymphoseek

* NAVIDEA BIOPHARMACEUTICALS ANNOUNCES ISSUANCE OF PATENT EXTENSION FOR LYMPHOSEEK® Source text for Eikon: Further company coverage:

BRIEF-Navidea Biopharmaceuticals Reports Q4 Loss Per Share Of $0.15

* NAVIDEA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up